EGFR and neoplasm: The poor outcome of high-risk patients might be ascribed to the activation of tumor progression-related pathways, such as ErbB signaling and the MAPK signaling pathway 29-30, while the functional enrichment of pathways associated with immune responses in low-risk patients contributed to their favorable outcomes.